| Journal Profile | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journal Title | OncoImmunology | ||||||||||||||||||||||||
| Journal Title Abbreviations | ONCOIMMUNOLOGY | ||||||||||||||||||||||||
| ISSN | 2162-4011 | ||||||||||||||||||||||||
| E-ISSN | 2162-402X | ||||||||||||||||||||||||
| h-index | 58 | ||||||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||||||
| Self-Citation Ratio (2020-2021) | 4.60% | ||||||||||||||||||||||||
| 期刊简介 | Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. | ||||||||||||||||||||||||
| Official Website | http://www.tandfonline.com/loi/koni20 | ||||||||||||||||||||||||
| Online Manuscript Submission | https://www.editorialmanager.com/ONCOIMM | ||||||||||||||||||||||||
| Open Access | No | ||||||||||||||||||||||||
| Publisher | 530 WALNUT STREET, STE 850, PHILADELPHIA, USA, PA, 19106 | ||||||||||||||||||||||||
| Subject Area | ONCOLOGY | ||||||||||||||||||||||||
| Country/Area of Publication | UNITED STATES | ||||||||||||||||||||||||
| Publication Frequency | |||||||||||||||||||||||||
| Year Publication Started | 0 | ||||||||||||||||||||||||
| Annual Article Volume | 114 | ||||||||||||||||||||||||
| Gold OA文章占比 | |||||||||||||||||||||||||
| OA期刊相关信息 | |||||||||||||||||||||||||
| WOS期刊SCI分区 | |||||||||||||||||||||||||
| Indexing (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||
| Link to PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2162-4011%5BISSN%5D | ||||||||||||||||||||||||
| Average Duration of Peer Review * | Authorized Data from Publisher: Data from Authors: 24 Weeks | ||||||||||||||||||||||||
| Competitiveness * | Data from Authors: | ||||||||||||||||||||||||
| Useful Links |
| ||||||||||||||||||||||||
| *All review process metrics, such as acceptance rate and review speed, are limited to our user-submitted manuscripts. As such they may not reflect the journals' exact competitiveness or speed. | |||||||||||||||||||||||||
|
|
| |
| First Previous 1 Next Last (To Page | |
| Reviews on OncoImmunology: | Write a review |
| Author: ILOVER Subject Area: Medicine Duration of Peer Review: 2.0 month(s) Result: Accepted after revision Write a review |
Reviewed 2020-12-23 08:20:07 Submitted at the end of August, and accepted at the end of December. During this period, it underwent a major revision, but without supplementing experiments, only answering the reviewer's questions. We delayed it and resubmitted the revision only after more than a month, and then it was directly accepted after two days. The overall feeling is quite good, processing and reviewing manuscripts are very fast, the impact factor is not bad, and you can try more in the future.  (0) Thank | ILOVER  |
| Author: Journals Subject Area: Medicine Duration of Peer Review: 2.0 month(s) Result: Accepted after revision Write a review |
Reviewed 2024-03-05 11:10:41 Submitted on August 1, 2023, received first round of major revision comments after 2 months; revised and sent back after 1 month, no time limit set for reviewers to continue review; received second round of major revision comments after 1 and a half months; revised after 1 month, received minor revision comments after around 1 month, and accepted after 3 days. Review was rigorous and feedback was constructive, a great opportunity to humbly learn true knowledge (0) Thank | Journals |
| First Previous 1 Next Last (To Page | |